As of 2025-09-18, the EV/EBITDA ratio of BridgeBio Pharma Inc (BBIO) is -18.81. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BridgeBio's latest enterprise value is 11,698.64 mil USD. BridgeBio's TTM EBITDA according to its financial statements is -622.03 mil USD. Dividing these 2 quantities gives us the above BridgeBio EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.5x - 14.7x | 13.8x |
| Forward P/E multiples | 14.2x - 16.8x | 16.0x |
| Fair Price | (56.28) - (57.85) | (58.50) |
| Upside | -210.0% - -213.0% | -214.3% |
| Date | EV/EBITDA |
| 2025-09-16 | -18.90 |
| 2025-09-15 | -18.90 |
| 2025-09-12 | -18.82 |
| 2025-09-11 | -19.24 |
| 2025-09-10 | -19.35 |
| 2025-09-09 | -19.52 |
| 2025-09-08 | -19.76 |
| 2025-09-05 | -19.48 |
| 2025-09-04 | -19.01 |
| 2025-09-03 | -19.01 |
| 2025-09-02 | -18.44 |
| 2025-08-29 | -18.99 |
| 2025-08-28 | -19.23 |
| 2025-08-27 | -18.32 |
| 2025-08-26 | -18.10 |
| 2025-08-25 | -17.61 |
| 2025-08-22 | -18.16 |
| 2025-08-21 | -18.52 |
| 2025-08-20 | -18.10 |
| 2025-08-19 | -18.11 |
| 2025-08-18 | -18.14 |
| 2025-08-15 | -18.85 |
| 2025-08-14 | -18.81 |
| 2025-08-13 | -18.56 |
| 2025-08-12 | -18.16 |
| 2025-08-11 | -17.90 |
| 2025-08-08 | -17.39 |
| 2025-08-07 | -17.20 |
| 2025-08-06 | -16.85 |
| 2025-08-05 | -18.20 |
| 2025-08-04 | -17.75 |
| 2025-08-01 | -17.64 |
| 2025-07-31 | -17.61 |
| 2025-07-30 | -17.10 |
| 2025-07-29 | -17.31 |
| 2025-07-28 | -17.29 |
| 2025-07-25 | -17.31 |
| 2025-07-24 | -17.11 |
| 2025-07-23 | -17.27 |
| 2025-07-22 | -17.14 |
| 2025-07-21 | -17.18 |
| 2025-07-18 | -17.37 |
| 2025-07-17 | -17.44 |
| 2025-07-16 | -17.55 |
| 2025-07-15 | -17.51 |
| 2025-07-14 | -17.73 |
| 2025-07-11 | -17.36 |
| 2025-07-10 | -17.30 |
| 2025-07-09 | -17.21 |
| 2025-07-08 | -16.35 |